Candel Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Candel Therapeutics, Inc. filed a Form 8-K reporting the results of its Annual Meeting of Stockholders held on June 28, 2023. The company’s common stock trades on Nasdaq under the symbol CADL. As of the May 19, 2023 record date, 28,919,810 shares of voting common stock were outstanding.
Financial and operating metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics. It is limited to shareholder voting results.
Material changes versus the prior comparable period
No financial or operating changes versus a prior period are disclosed.
Meeting results, outlook, and unusual items
- Stockholders elected all three Class II director nominees for three-year terms expiring at the 2026 annual meeting: Edward J. Benz Jr., M.D.; Paul B. Manning; and Paul Peter Tak, M.D., Ph.D., FMedSci.
- Votes for the director nominees were 10,762,707 for Dr. Benz, 10,903,287 for Mr. Manning, and 10,930,887 for Dr. Tak. Broker non-votes totaled 4,502,642 for each nominee.
- Stockholders ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 15,388,012 votes for, 82,122 against, and 1,081 abstaining.
- No other matters were submitted to or voted on at the meeting.
- The filing provides no management guidance, business outlook, risk update, contingency disclosure, or unusual financial item.
Important facts for investors to verify
- Confirm the election status and subsequent service of the three Class II directors through later filings.
- Confirm KPMG LLP’s continued appointment and any subsequent auditor changes.
- Review the company’s periodic reports for financial results, cash runway, financing needs, clinical-development progress, and related risks, none of which are addressed in this 8-K.